These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23788755)

  • 1. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
    Johnsson A; Hagman H; Frödin JE; Berglund A; Keldsen N; Fernebro E; Sundberg J; De Pont Christensen R; Garm Spindler KL; Bergström D; Jakobsen A
    Ann Oncol; 2013 Sep; 24(9):2335-41. PubMed ID: 23788755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
    Hansen TF; Christensen Rd; Andersen RF; Sørensen FB; Johnsson A; Jakobsen A
    Br J Cancer; 2013 Sep; 109(5):1243-51. PubMed ID: 23922111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.
    Hagman H; Frödin JE; Berglund Å; Sundberg J; Vestermark LW; Albertsson M; Fernebro E; Johnsson A
    Ann Oncol; 2016 Jan; 27(1):140-7. PubMed ID: 26483047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
    Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
    J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
    Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
    Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
    Tournigand C; Chibaudel B; Samson B; Scheithauer W; Vernerey D; Mésange P; Lledo G; Viret F; Ramée JF; Tubiana-Mathieu N; Dauba J; Dupuis O; Rinaldi Y; Mabro M; Aucoin N; Latreille J; Bonnetain F; Louvet C; Larsen AK; André T; de Gramont A
    Lancet Oncol; 2015 Nov; 16(15):1493-1505. PubMed ID: 26474518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
    Herbst RS; Ansari R; Bustin F; Flynn P; Hart L; Otterson GA; Vlahovic G; Soh CH; O'Connor P; Hainsworth J
    Lancet; 2011 May; 377(9780):1846-54. PubMed ID: 21621716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
    Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
    Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
    Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
    J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
    Cohen EE; Davis DW; Karrison TG; Seiwert TY; Wong SJ; Nattam S; Kozloff MF; Clark JI; Yan DH; Liu W; Pierce C; Dancey JE; Stenson K; Blair E; Dekker A; Vokes EE
    Lancet Oncol; 2009 Mar; 10(3):247-57. PubMed ID: 19201650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.
    Xu W; Gong Y; Kuang M; Wu P; Cao C; Chen J; Tang C
    Clin Drug Investig; 2017 Feb; 37(2):155-165. PubMed ID: 27665469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
    Díaz-Rubio E; Gómez-España A; Massutí B; Sastre J; Abad A; Valladares M; Rivera F; Safont MJ; Martínez de Prado P; Gallén M; González E; Marcuello E; Benavides M; Fernández-Martos C; Losa F; Escudero P; Arrivi A; Cervantes A; Dueñas R; López-Ladrón A; Lacasta A; Llanos M; Tabernero JM; Antón A; Aranda E;
    Oncologist; 2012; 17(1):15-25. PubMed ID: 22234633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study.
    Moscetti L; Nelli F; Fabbri MA; Sperduti I; Alesini D; Cortesi E; Gemma D; Gamucci T; Grande R; Pavese I; Franco D; Ruggeri EM
    Invest New Drugs; 2013 Aug; 31(4):1035-43. PubMed ID: 23417697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
    Groen HJ; Socinski MA; Grossi F; Juhasz E; Gridelli C; Baas P; Butts CA; Chmielowska E; Usari T; Selaru P; Harmon C; Williams JA; Gao F; Tye L; Chao RC; Blumenschein GR
    Ann Oncol; 2013 Sep; 24(9):2382-9. PubMed ID: 23788751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
    Kubicka S; Greil R; André T; Bennouna J; Sastre J; Van Cutsem E; von Moos R; Osterlund P; Reyes-Rivera I; Müller T; Makrutzki M; Arnold D;
    Ann Oncol; 2013 Sep; 24(9):2342-9. PubMed ID: 23852309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer.
    Zhao Z; Li J; Ye R; Wu X; Gao L; Niu B
    Medicine (Baltimore); 2017 Jul; 96(30):e7182. PubMed ID: 28746175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
    Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S;
    Lancet Oncol; 2013 Jan; 14(1):29-37. PubMed ID: 23168366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
    Yalcin S; Uslu R; Dane F; Yilmaz U; Zengin N; Buyukunal E; Buyukberber S; Camci C; Sencan O; Kilickap S; Ozdener F; Cevik D
    Oncology; 2013; 85(6):328-35. PubMed ID: 24247559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.